Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The ribosome peptidyl transferase center (PTC) – nascent peptide complex is the catalytic core of the ribosome responsible for the formation of peptide bonds during protein synthesis (Steitz & Moore, 2003, DOI: 10.1016/S0968-0004(03)00171-6). This complex, primarily composed of ribosomal RNA (rRNA), acts as a ribozyme within the large ribosomal subunit to facilitate the transfer of the growing polypeptide chain from the peptidyl-tRNA to the incoming aminoacyl-tRNA (Polikanov et al., 2014, DOI: 10.1016/j.molcel.2014.09.020). The nascent peptide complex specifically describes the state where the newly synthesized polypeptide is threaded through the ribosomal exit tunnel, a path that can influence protein folding and translation rates (Wilson, 2014, DOI: 10.1038/nrmicro3355). As a primary therapeutic target, the PTC and its associated exit tunnel are the binding sites for numerous antibiotic classes, including macrolides, oxazolidinones, and pleuromutilins, which disrupt bacterial growth by stalling translation (Dunkle et al., 2010, DOI: 10.1126/science.1192661). In addition to antimicrobial therapy, this complex is a target for nonsense suppression agents like ataluren, which aim to treat genetic diseases by promoting the read-through of premature stop codons (Lentini et al., 2014, DOI: 10.1016/j.molmed.2014.01.010). However, the high conservation of the PTC across domains of life presents challenges, as some inhibitors can cross-react with human mitochondrial ribosomes, leading to clinical toxicities such as myelosuppression and neuropathy (Böttger et al., 2001, DOI: 10.1046/j.1365-2958.2001.02335.x). Understanding the structural dynamics of the PTC-nascent peptide interaction is essential for overcoming antibiotic resistance and developing precision medicines for translation-related pathologies.
Inhibition of peptide bond formation through competitive binding at the ribosomal A-site or P-site, or steric blockage of the nascent peptide exit tunnel to prevent polypeptide elongation.
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosome peptidyl transferase center – nascent peptide complex (PTC-NC).